The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER by Stagg, Helen R et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The TRC8 E3 ligase ubiquitinates MHC class I molecules before
dislocation from the ER
Citation for published version:
Stagg, HR, Thomas, M, van den Boomen, D, Wiertz, EJHJ, Drabkin, HA, Gemmill, RM & Lehner, PJ 2009,
'The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER', Journal of Cell
Biology, vol. 186, no. 5, pp. 685-92. https://doi.org/10.1083/jcb.200906110
Digital Object Identifier (DOI):
10.1083/jcb.200906110
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Cell Biology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 04. Jan. 2021
The Rockefeller University Press  $30.00
J. Cell Biol. Vol. 186 No. 5 685–692
www.jcb.org/cgi/doi/10.1083/jcb.200906110 JCB 685
JCB: REPORT
H.R. Stagg and M. Thomas contributed equally to this paper.
Correspondence to Paul J. Lehner: pjl30@cam.ac.uk
Abbreviations used in this paper: ERAD, ER-associated degradation; MHC I, 
major histocompatibility complex class I; RING, really interesting new gene; 
shRNA, short hairpin RNA; SPP, signal peptide peptidase.
Introduction
The ER quality control system ensures that nonnative or mis-
folded proteins are targeted for dislocation from the ER to 
the cytosol and degraded by the proteasome as part of the ER-
associated degradation (ERAD) pathway (Vembar and Brodsky, 
2008; Hirsch et al., 2009). ERAD is implicated in a wide 
variety of cellular processes, including cystic fibrosis, the ser-
pinopathies such as 1-antitrypsin deficiency, and aggrega-
tion disorders, as seen with neurodegenerative diseases. An 
essential step in ERAD is ubiquitination of the protein sub-
strate, a process which precedes or accompanies retrotranslo-
cation of integral membrane proteins. The E3 ligase is the key 
enzyme in the dislocation pathway and crucial for substrate 
extraction, recognition, and degradation by the proteasome. 
The generation of a polyubiquitinated substrate requires three 
enzymes. The E1 ubiquitin–activating enzyme covalently ac-
tivates and adds ubiquitin to an E2 ubiquitin–conjugating en-
zyme. Ubiquitin is then transferred from the ubiquitin-charged 
E2 to either the substrate or the growing ubiquitin chain by 
the action of the E3 ubiquitin ligase, which therefore confers 
the main element of specificity to the reaction. Current esti-
mates suggest that there are two E1 enzymes, around 40 E2 
enzymes, and several hundred E3 ligases, including the HECT 
(homologous to E6-AP C terminus) domain E3s, the RING 
(really interesting new gene) E3s, and the U box proteins (Li 
et al., 2008).
In yeast, the multimembrane-spanning, ER-resident Doa10 
and Hrd1 (hydroxymethylglutaryl-CoA reductase degradation 1) 
E3 ligases are implicated in the degradation of every studied 
ubiquitinated ERAD substrate (Vembar and Brodsky, 2008). 
This contrasts with the greatly expanded mammalian reper-
toire of ERAD E3 ligases (Kostova et al., 2007), which include 
yeast Hrd1 homologues HRD1 and gp78, whereas MARCHVI 
(TEB4) is the Doa10 orthologue. Additional E3 ligases of the 
mammalian ERAD pathway include RMA1, which cooperates 
with gp78 to target mutant cystic fibrosis transport regulator for 
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a library of siRNAs that target ubiquitin E3 ligases in a genetic 
screen to identify siRNAs capable of rescuing US2-mediated 
MHC I degradation. The screen revealed that depletion of the 
TRC8 (translocation in renal carcinoma, chromosome 8 gene) 
E3 ligase leads to a loss of MHC I ubiquitination and disloca-
tion and a dramatic rescue of MHC I to the cell surface in US2-
expressing cells. These results implicate TRC8 as the E3 ligase 
required for MHC I ubiquitination and identify a novel ER com-
plex involved in mammalian ERAD.
Results and discussion
An siRNA screen identifies TRC8 as  
the E3 ligase required for US2-mediated 
MHC I dislocation
To identify the E3 ligase or ligases responsible for US2-mediated 
MHC I ubiquitination, we screened a custom siRNA library 
targeting putative members of the E3 ligase family (consist-
ing of bioinformatically collated RING, HECT, and U box E3 
ligases; Li et al., 2008) on HeLa cells stably expressing a lu-
menal GFP–MHC I heavy chain fusion protein (GFP-HLA-A2) 
and US2. Expression of US2 or US11 down-regulates cell sur-
face MHC I (Fig. 1 A) as well as the GFP reporter (Fig. S1). 
We predicted that depletion of an E3 ligase responsible for US2-
mediated MHC I ubiquitination would rescue GFP-HLA-A2 
from proteasome-mediated degradation. Therefore, we used 
GFP-HLA-A2 fluorescence as an optical readout in a flow 
cytometry–based screen to identify the cellular E3 ligase recruited 
by US2. A related emerald GFP–MHC I chimera was previously 
shown to behave similarly to endogenous MHC I, including 
being targeted for retrograde translocation and proteasome- 
mediated degradation by US2 (Fiebiger et al., 2002). In control 
cells, GFP-HLA-A2 is expressed at the cell surface; expression of 
US2 causes proteasome-mediated degradation of GFP-HLA-A2 
with a concomitant loss of fluorescence signal, which is rescued 
after proteasome inhibition (Fig. S1).
HeLa GFP-HLA-A2 cells stably expressing US2 were 
screened with a custom RNAi library using high throughput 
96-well flow cytometry. Of the 373 ligases screened, only siRNA-
mediated depletion of TRC8 (Z score 11.57) gave a significant 
rescue in fluorescence signal (Fig. 1, B and C, top) above the 
Bonferroni-corrected p-value threshold (P = 0.05) of 3.82. This 
rescue in fluorescence signal was achieved with four indepen-
dent TRC8 siRNAs targeting oligonucleotides (Fig. S2 A). 
In the same US2-expressing HeLa cells, siRNA-mediated TRC8 
depletion completely restored cell surface expression of endog-
enous MHC I (Fig. 1 C, bottom), an effect seen with all four 
TRC8-specific oligonucleotides (Fig. S2 B), as did doxycycline-
induced TRC8 short hairpin RNA (shRNA) expression in 
HEK-293–US2 cells (Fig. 1 D). In contrast, in HeLa GFP-HLA-A2 
US11-expressing cells, TRC8 depletion had no effect on either 
GFP-HLA-A2 fluorescence or MHC I cell surface expression 
(Fig. 1 C), implying that US2 utilizes a specific and distinct 
ERAD pathway.
Effective depletion of TRC8 was confirmed for all four 
individual siRNA oligonucleotides of the original pool by 
immunoblotting for endogenous TRC8, with no effect against 
ERAD (Younger et al., 2006). Some of the additional 40–50 
uncharacterized RING E3 ligases with predicted transmem-
brane segments are also likely to be involved in ERAD.
US2 and US11 are two well-characterized viral genes 
from human cytomegalovirus whose expression causes down-
regulation of cell surface major histocompatibility complex 
class I (MHC I; Wiertz et al., 1996a,b). The US2 and US11 
viral gene products have been instrumental in both defining 
the mammalian ERAD pathway and identifying novel com-
ponents of the ERAD system. MHC I molecules play an es-
sential role in the adaptive immune system, specifically in 
the defense against intracellular infections. They bind small 
peptides in the lumen of the ER and traffic them to the cell 
surface for presentation to cytotoxic T lymphocytes. Peptides 
derived from viruses are recognized as foreign, ensuring 
infected cells are killed by circulating cytotoxic T lympho-
cytes, thus preventing viral dissemination. The importance of 
the MHC I pathway is highlighted by the multiple strategies 
used particularly by the large double-stranded DNA viruses 
to prevent the presentation of viral peptides by disrupting the 
assembly and trafficking of MHC I, leading to decreased cell 
surface MHC I expression.
The US2 and US11 genes encode ER-resident mem-
brane glycoproteins, which bind newly synthesized MHC I 
in the lumen of the ER. They initiate the dislocation of MHC I 
from the ER back to the cytosol before proteasome-mediated 
degradation (Wiertz et al., 1996a,b). Despite the apparent 
similarities in US2- and US11-mediated MHC I degradation, 
these two viral proteins use distinct ERAD pathways for 
MHC I dislocation. The US11 ERAD pathway is the better 
characterized and helped identify the Derlin-1–SEL1L com-
plex (Lilley and Ploegh, 2004; Ye et al., 2004; Mueller et al., 
2006), emphasizing the utility of these viral genes in defining 
ERAD components (Lilley and Ploegh, 2004; Mueller et al., 
2006). Derlin-1 associates with the two ERAD E3 ligases 
HRD1 and gp78 (Lilley and Ploegh, 2005), although their 
involvement in US11-mediated MHC I dislocation has not 
been elucidated (Kikkert et al., 2004). SEL1L, the mammalian 
homologue of yeast Hrd3p, is required for US11-mediated 
MHC I dislocation (Mueller et al., 2006) and also helped 
identify additional components of the degradation complex 
(Mueller et al., 2008). Less progress has been made on the Derlin-
independent US2 dislocation pathway. Signal peptide pepti-
dase (SPP), a presenilin-like aspartyl protease which cleaves 
polypeptides within the membrane, is essential for US2-mediated 
MHC I degradation (Loureiro et al., 2006), although its function 
is unclear.
Despite US2 showing a critical requirement for a func-
tional ubiquitin system (Hassink et al., 2006) and ubiquitination 
being detected in US2-mediated MHC I degradation, the E3 
ligase responsible for US2-mediated MHC I ubiquitination has 
remained elusive (Shamu et al., 2001; Furman et al., 2003; Hassink 
et al., 2006). US2 has no intrinsic E3 ligase activity itself but 
recruits newly synthesized MHC I molecules to the ERAD path-
way. Therefore, the cellular ubiquitination machinery must par-
ticipate in MHC I dislocation, but immunopurifications of the 
US2 complex have not identified candidate E3 ligases. We used 
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Figure 1. An siRNA ubiquitin ligase screen identifies a 
requirement for TRC8 in MHC I dislocation. (A–F) siRNA- 
mediated TRC8 depletion rescues MHC I from US2-mediated 
dislocation. (A) Cytofluorometric analysis of cell surface 
MHC I in HeLa and US2- or US11-expressing HeLa cells 
demonstrating MHC I down-regulation. (B) Of the 373 E3 
ligases screened, only TRC8 depletion gave a significant 
rescue in fluorescence signal with a Z score of 11.57. 
The bar chart shows the Z scores for the 60 genes on the 
TRC8-containing library plate. The dashed lines indicate 
the Bonferroni-corrected p-value threshold of 3.82 for the 
entire siRNA library. The graph on the right shows that the 
TRC8 siRNA pool caused the only significant increase in 
fluorescence signal. Error bars indicate standard error of 
the mean. (C) Cytofluorometric analysis of GFP (top) and 
MHC I (bottom) in GFP-HLA-A2–expressing HeLa, +US2, 
and +US11 cells after mock or TRC8 siRNA depletion. 
KD, knockdown. (D) US2-mediated MHC I down-regulation 
is also rescued by a doxycycline-inducible anti-TRC8 shRNA. 
Cytofluorometric analysis of MHC I in HEK-293–US2 cells 
(black dotted line) and doxycycline-induced TRC8 shRNA 
expression (black line) is shown. (E) Immunoblot analysis 
of endogenous TRC8 and control calreticulin levels in cells 
after siRNA mock (Mk) or TRC8 depletion with a pool 
of or individual (#1–4) TRC8-specific oligonucleotides. 
(F) Immunoblot analysis of MHC I heavy chain and control 
(ctrl; EGF receptor [EGFR]) in US2- and US11-expressing 
HeLa cells after mock or TRC8 siRNA depletion. MHC I 
heavy chain is rescued after TRC8 depletion. (E and F) 
Molecular mass is indicated in kilodaltons.
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unrelated calreticulin, confirming specificity (Fig. 1 E). Although 
depletion of TRC8 had little effect on endogenous MHC I 
heavy chain expression in control or US11-expressing HeLa 
cells, a rescue of MHC I heavy chain is seen by immunoblot 
in TRC8 siRNA–treated US2-expressing cells (Fig. 1 F).
TRC8 depletion rescues MHC I from the 
cytosol to the membrane fraction and is 
responsible for MHC I ubiquitination
The signature of US2-mediated degradation of MHC I heavy 
chains is the appearance of a nonmembrane-bound, soluble, 
deglycosylated MHC I heavy chain, which is visualized as 
a faster migrating species in the presence of proteasome 
inhibitors (Wiertz et al., 1996b). The increased mobility re-
sults from cytosolic peptide: N-glycanase–mediated removal 
of the single N-linked MHC I glycan (Blom et al., 2004). 
To further determine the effect of TRC8 on MHC I degrada-
tion, we fractionated cells to separate membrane-bound and 
soluble cytosolic heavy chain (Hughes et al., 1997). After 
solubilization in Triton X-100, MHC I heavy chains were 
immunoprecipitated and visualized by immunoblotting. Immuno-
precipitations with the HC10 antibody identified heavy chain 
in the membrane fraction of control cells (Fig. 2 A, lane 1). 
In contrast, in US2-expressing cells, heavy chain is pre-
dominantly isolated from the soluble cytosolic pool as the 
deglycosylated species (Fig. 2 A, lane 7). TRC8 depletion 
from US2-expressing cells shows a rescue of MHC I from 
the cytosolic to the membrane fraction as detected by the 
HC10 antibody, which recognizes unfolded MHC I (Fig. 2 A, 
lanes 6 and 8). This TRC8-mediated rescue was confirmed 
by immunoprecipitation with the MHC I–specific antibody 
(w6/32), which recognizes a conformation-dependent epi-
tope on the lumenal domain of MHC I and showed a rescue 
of folded MHC I to the membrane fraction (Fig. 2 A, bottom, 
lane 5 vs. lane 6), which is consistent with the flow cytome-
try data (Fig. 1 C). Therefore, TRC8 is an ER ligase required 
for US2-mediated MHC I degradation.
To determine the effect of TRC8 on MHC I ubiquitina-
tion, MHC I molecules were immunoprecipitated from radio-
labeled cells with the w6/32 antibody (Furman et al., 2003). 
Samples were denatured in 1% SDS and reprecipitated with 
either heavy chain (HC10)– or polyubiquitin (P4D1)-specific 
antibodies. In US2-expressing but not control cells, reprecip-
itation with HC10 showed additional higher molecular mass 
bands above the 44-kD MHC I heavy chain, which were con-
firmed as ubiquitinated MHC I species by immunoprecipi-
tation with the P4D1 antibody (Fig. 2 B, lane 6). TRC8 depletion 
of the US2-expressing cells resulted in a 76% loss of these 
ubiquitinated MHC I species (Fig. 2 C). Collectively, these 
results show that TRC8 is essential for MHC I dislocation and Figure 2. US2-dependent MHC I dislocation and ubiquitination are abol-
ished after TRC8 depletion. (A) Cellular fractionation shows that TRC8 
depletion rescues MHC I from the soluble to the membrane fraction. siRNA 
mock (Mk) or TRC8-depleted cells ± US2 were separated into membrane 
(M) and soluble (S) fractions. MHC I was immunoprecipitated (mAb HC10 
or w6/32) from each fraction and visualized by immunoblot analysis (mAb 
3B10.7). After TRC8 depletion, conformational MHC I is found in the mem-
brane fraction. (B and C) TRC8 depletion prevents MHC I ubiquitination. 
(B) Detergent lysates from 20-min radiolabeled control (ctrl) and US2 cells 
were immunoprecipitated with the MHC I (w6/32) mAb, denatured, and 
reprecipitated with heavy chain (HC10)– or polyubiquitin (P4D1)-specific 
mAb. HC10 precipitates were confirmed as ubiquitinated MHC I species. 
(C) siRNA mock or TRC8-depleted control and US2 cells were treated 
as in B. Ubiquitinated MHC I species were lost after TRC8 depletion. 
(A–C) Molecular mass is indicated in kilodaltons. 1°, primary; 2°, secondary; 
HC, heavy chain; IP, immunoprecipitation.
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et al., 2002) predicted to span the membrane up to 10 times. Its 
C terminus has the defining feature of RING-type E3 ligases, 
a RING-H2 domain which coordinates zinc binding and was 
shown to catalyze in vitro ubiquitination (Brauweiler et al., 
2007). To assess the requirement for a functional RING on 
TRC8 in vivo activity, we compared overexpression of wild-
type and TRC8 RING mutants on cell surface MHC I levels in 
US2-expressing HeLa cells. Overexpression of wild-type TRC8 
potentiated MHC I down-regulation (Fig. 3 A). The opposite 
effect was seen with both a TRC8 RING-less (RING) and a TRC8 
RING mutant (SAIS), in which two of the zinc-coordinating 
Cys residues are replaced with Ser residues, mutations which 
are known to destabilize the RING. Overexpression of either 
of these RING mutants increased cell surface MHC I to normal 
ubiquitination. After TRC8 depletion, the MHC I is neither 
ubiquitinated nor retained in the ER but traffics normally to 
the cell surface despite the presence of US2.
TRC8 RING mutants act as dominant 
negatives and rescue MHC I back to the 
cell surface
The TRC8 gene was originally identified in a family with 
hereditary kidney and thyroid cancer caused by a chromosomal 
translocation t(3;8)(3p14;q24.1); the disruption of TRC8 at 8q24 
permitted its positional cloning and further analysis (Gemmill 
et al., 1998). TRC8 mutations were subsequently identified in 
sporadic cases of kidney cancer (Gemmill et al., 1998; Poland 
et al., 2007). TRC8 is a 66-kD ER-resident protein (Gemmill 
Figure 3. TRC8 RING mutants act as dominant negative to rescue US2-mediated MHC I down-regulation. (A) Cytofluorometric analysis of MHC I in US2-
expressing HeLa cells (black dotted lines) transfected with wild-type (wt) TRC8, RING TRC8, or a RING Cys-Ser mutant TRC8 (SAIS; black lines). In the 
absence of a functional RING, MHC I is rescued to the cell surface. (B) Overexpression of wild-type TRC8 increases deglycosylated US2, whereas RING 
TRC8 stabilizes glycosylated US2. Immunoblot analysis of TRC8 and US2 in wild-type TRC8 and HA–RING TRC8–inducible HEK-293 cells ± doxycycline 
(Dox). Ubc13 is the loading control (ctrl). Molecular mass is indicated in kilodaltons.
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(Fig. 4 B). Glycosylated and deglycosylated US2 (20–23 kD) and 
MHC I heavy chain (44 kD) as well as monomeric (40–45 kD) 
forms of SPP were identified in association with TRC8. Identi-
cal reprecipitations from the same cells expressing wild-type 
TRC8 confirmed the association of MHC I and SPP with TRC8 
(Fig. S3 A), although the MHC I band is weaker. The association 
of SPP and MHC I with TRC8 was also visualized in radio-
labeled TRC8- and SPP-transfected HeLa-US2 cells (Fig. 4 C). 
Furthermore, SPP and TRC8 interact in the absence of US2 
(Fig. 4 D), an interaction which was also confirmed with endog-
enous SPP (Fig. S3 B).
Our work identifies TRC8 as a novel ERAD ubiquitin E3 
ligase recruited by US2 for the ubiquitination and dislocation of 
MHC I. The rescue of folded, mature MHC I back to the cell 
surface after TRC8 depletion suggests that for MHC I mole-
cules, ubiquitination is an early, reversible event that pre-
cedes dislocation. Depletion of the mammalian E3 ligase 
gp78 resulted in the accumulation of its substrate CD3- in the 
ER membrane, also suggesting that ubiquitination was an early 
event that preceded dislocation (Chen et al., 2006). Any residual 
degradation likely reflects incomplete depletion of TRC8, but a 
subsidiary role of an additional ligase cannot be excluded.
Both the cytosolic tail and the transmembrane domain of 
US2 are critical for function (Furman et al., 2002; Chevalier and 
Johnson, 2003). Its tail interacts with SPP (Loureiro et al., 2006) 
and the p97 ATPase (Chevalier and Johnson, 2003), and engage-
ment of TRC8 is likely to occur via the transmembrane domain. 
levels despite the presence of US2 (Fig. 3 A). Furthermore, 
doxycycline-induced expression of the RING-less TRC8 mu-
tant in HEK-293 cells stabilized the more abundant glycosyl-
ated form of US2, whereas induction of wild-type TRC8 caused 
an increase in the faster migrating deglycosylated form of US2 
(Fig. 3 B). Together, these results predict an interaction between 
TRC8 and US2 (as shown in Fig. 4), with the TRC8 RING mu-
tants acting as dominant-negative forms competing with endog-
enous TRC8 for binding to US2.
TRC8 associates in the ER with US2, 
MHC I, and SSP
The identification of proteins binding to E3 ligases is often 
facilitated by the use of RING mutants. To identify poten-
tial TRC8-binding partners, doxycycline-induced, HA-tagged 
TRC8 RING mutant HEK-293 cells (Brauweiler et al., 2007) 
transfected with US2 were radiolabeled and immunoprecipi-
tated with anti-HA antibody (Fig. 4 A, lane 1). Together with 
the TRC8 RING mutant (66 kD), prominent additional bands 
are detected at 20–23, 40–45, and 97 kD (Fig. 4 A, lane 1). The 
bands in the 40–45-kD region could represent either MHC I 
(44 kD) or SPP, which also runs at a similar molecular mass 
and is required for US2-mediated MHC I dislocation. To further 
delineate these bands, we repeated the same HA-specific pri-
mary immunoprecipitation on radiolabeled cells cotransfected 
with SPP and, after dissociating the complex in SDS, reprecipi-
tated with US2-, MHC I (HCA2)–, and SPP-specific antibodies 
Figure 4. TRC8 forms a multimolecular ER 
complex with MHC I, US2, and SPP. (A) Doxy-
cycline-induced, HA–RING TRC8 HEK-293 
cells transfected with US2 were radiolabeled 
for 30 min, and lysates were immunoprecipi-
tated with HA or normal rabbit serum (NRS) 
control. (B) Doxycycline-induced HA–RING 
TRC8 HEK-293 cells transfected with US2 and 
SPP were radiolabeled and immunoprecipitated 
with HA as in A, and samples were denatured 
and reprecipitated with normal rabbit serum, 
US2, SPP, or MHC I heavy chain (HCA2). 
(C) US2-expressing HeLa cells transfected with 
HA–RING TRC8 were radiolabeled, and 
immunoprecipitations were performed as in 
B, or the cells were reprecipitated with MHC 
I heavy chain (HC10). (D) HA–RING TRC8– 
overexpressing HEK-293 cells were radiolabeled, 
and immunoprecipitations were performed 
as in B. (A–D) Molecular mass is indicated 
in kilodaltons. 1°, primary; 2°, secondary; 
IP, immunoprecipitation.
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controls. Plates were screened n = 1 or n = 2 when it appeared a hit might 
be present. Data were normalized to mock-transfected controls (five on 
each plate), and the mean was taken of repeats where present. Z scores 
were calculated from the mean and standard deviation of the entire data-
set. Using a Bonferroni-corrected p-value (0.05), a Z score of >3.82 is sta-
tistically significant. TRC8 depletion yielded a Z score of 11.57.
Cell culture
HeLa cells were stably transduced with pK1 GFP-HLA-A2 (a gift from 
L. Boyle, University of Cambridge, Cambridge, England, UK; Boyle et al., 
2006). GFP-HLA-A2–expressing HeLa cells were subsequently transduced 
with the retroviral constructs pLZRS US2-IRES-NGFR or pLZRS US11-IRES-
NGFR (Hassink et al., 2006). Doxycycline-inducible HEK-293 TRC8 
cells were previously described (Brauweiler et al., 2007). In brief, TRC8-HA 
in GFPC1 (Gemmill et al., 2002) was transferred to pcDNA5/FRT/TO 
using KpnI and verified by sequence analysis. Site-directed mutagenesis 
generated all RING mutations. HEK-293 FlpIn lines carrying doxycycline-
inducible constructs were generated by cotransfection of pcDNA5/FRT/
TO with pOG44 encoding flippase-recombinase. After 2 d, recombinant 
cells were selected in 50 µg/ml hygromycin B (Invitrogen) and 5 µg/ml 
blasticidin (Invitrogen).
Antibodies
The following antibodies were used: rabbit anti-HA (Sigma-Aldrich), rabbit 
anti-SPP (Abcam), mouse anti-TRC8 (Abnova), mouse anti–ubiquitin P4D1 
(Santa Cruz Biotechnology, Inc.), rabbit anti-Ubc13 (AbD Serotec), mouse 
anticalreticulin (Thermo Fisher Scientific), rabbit anti–EGF receptor (Santa 
Cruz Biotechnology, Inc.), mouse mAb HC10 (anti–MHC I heavy chain), 
mouse mAb HCA2 (anti–MHC I heavy chain), mouse w6/32 (anti–MHC I), 
rat 3B10.7 (anti–MHC I heavy chain), and rabbit anti-US2 (177-5).
Constructs
Tetracycline-inducible shRNA expression constructs were designed based 
on TRC8 siRNA (Applied Biosystems) and inserted into pSuperior.puro. 
Reverse complementary oligonucleotides were synthesized with the following 
sequences: forward, 5-GATCCGCTTGACGATTATGTCTACTTCAAGAGA-
GTAGACATAATCGTCAAGCTTTTTTGGCCC-3; and reverse, 5-TCGAG-
GGCCAAAAAAGCTTGACGATTATGTCTACTCTCTTGAAGTAGACATA-
ATCGTCAAGCG-3. Stable transfectants in HEK-293 FlpIn TRex cells 
were selected with 3 µg/ml puromycin and 5 µg/ml blasticidin. Human 
SPP cDNA (Strausberg et al., 2002) was cloned into pCMV SPORT6.0 
(a gift from P. St. George-Hyslop, University of Cambridge, Cambridge, 
England, UK). US2 transfections were performed using pCIneo US2.
Flow cytometry
HeLa or HEK-293 cells were stained with the mAb w6/32 in PBS and visual-
ized with goat anti–mouse Cy5-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories). Cells were fixed in PBS with 1% PFA 
(AnalaR BDH), read on a FACSCalibur (BD), and analyzed in FlowJo.
Radiolabeling and immunoprecipitation
In brief, cells were treated with 20 µM MG132 (EMD) in starve and pulse. 
Cells were starved for 30 min in Met- and Cys-free medium and labeled 
with [35S]Met and [35S]Cys for the indicated time periods. N-ethylmaleimide 
(Sigma-Aldrich) was added to cells 2 min before lysis at 0.5 mM and solu-
bilized in 1% Triton X-100 or 1% digitonin in 10 mM Tris and 150 mM NaCl 
(TBS), pH 7.4, containing 1 mM iodoacetamide (Sigma-Aldrich), 0.5 mM 
PMSF (Sigma-Aldrich), and protease inhibitor cocktail tablets (Roche). After 
a protein A–Sepharose preclear, samples were immunoprecipitated with 
the indicated antibody and protein A–Sepharose for 1–3 h. For reimmuno-
precipitations, samples were dissociated with 1% SDS-TBS and, after SDS 
sequestration, with 1% Triton X-100 and reimmunoprecipitated for 12 h. 
After washing in 0.1% lysis buffer, immunoprecipitates were dissociated 
from the beads at 70°C in SDS-reducing sample buffer, separated by SDS-
PAGE, processed for autoradiography with a STORM scanner (GE Health-
care), and analyzed with ImageQuant TL (GE Healthcare). Visualization of 
ubiquitin bands required autoradiography for 5–14 d.
Cell fractionation and immunoblotting
After a 3-h incubation with MG132 at 37°C, cells were fractionated by 
freeze–thaw permeabilization (Hughes et al., 1997), and the nuclear fraction 
was removed. Membranes were pelleted by ultracentrifugation at 100,000 
g for 1 h, and both membrane and cytosolic fractions were solubilized in 
1% Triton X-100. Samples were immunoprecipitated, separated by SDS-
PAGE (8, 9, or 10% Tris-Gly gels), and after transfer onto polyvinylidene 
The role of SPP in the TRC8 complex remains undefined, in 
particular whether this multimembrane-spanning protein uti-
lizes its aspartic protease activity, as no requirement for SPP 
catalytic activity in the dislocation process has been reported. It 
is tempting to speculate that after the SPP-mediated intramem-
brane cleavage of substrate polypeptides, there is an additional 
requirement for ubiquitination by TRC8 to target cleaved sub-
strates for dislocation and degradation. However, SPP-mediated 
intramembrane cleavage has not been seen for either MHC I or 
US2. An alternative possibility is that the transmembrane seg-
ments of the multimembrane-spanning E3 ligases together with 
SPP either form or contribute to the retrotranslocation channel, as 
has been suggested for the yeast E3 ligases (Kreft et al., 2006; 
Kostova et al., 2007).
In addition to its RING domain, TRC8 also possesses a 
putative sterol-sensing domain, which is identified in a diverse 
range of membrane proteins, including hydroxymethylglutaryl-
CoA reductase and Patched (Gemmill et al., 1998), but not seen 
in other E3 ligases. Overexpression of TRC8 represses genes 
involved in cholesterol and fatty acid biosynthesis that are tran-
scriptionally regulated by the sterol response element-binding 
proteins, although how TRC8 regulates these proteins is unclear 
(Brauweiler et al., 2007). Sterol-sensing domains play a role in 
cholesterol homeostasis as well as vesicle trafficking and could 
therefore provide a link between the proposed role for lipids 
and lipid droplet formation with the dislocation of proteins 
from the ER (Ploegh, 2007). However, effective sterol depletion 
with lipoprotein-depleted serum, mevastatin, mevalonate, and 
hydroxypropyl--cyclodextrin did not affect down-regulation of 
MHC I by US2 (unpublished data).
The involvement of TRC8 in both hereditary and sporadic 
cases of clear cell renal carcinoma is intriguing, particularly 
as TRC8 is the second E3 ligase, after the von Hippel-Lindau 
gene product, to be implicated in the etiology of renal tumors. 
Because disruption of TRC8 predisposes to renal cell carci-
noma, increasing levels of proteins usually disposed of by TRC8 
may be involved in tumor development, making the identifica-
tion of physiological substrates of this novel ERAD E3 ligase 
all the more imperative.
Materials and methods
RNAi screening
Cells were reverse transfected with a custom E3 ubiquitin ligase siRNA 
library (Thermo Fisher Scientific) using Oligofectamine (Invitrogen). Each 
gene was targeted with an siRNA pool of four individual oligonucleotides. 
The 373 candidate E3 ligases were determined bioinformatically using 
InterPro family accessions (http://www.ebi.ac.uk/interpro), the Human 
Protein Reference Database (http://www.hprd.org), and National Center 
for Biotechnology Information Entrez Gene RefSeq accessions (http://www 
.ncbi.nlm.nih.gov/sites/entrez?db=gene). The TRC8 siRNA pool was sub-
sequently deconvoluted into four individual oligonucleotides (oligonucleotide 
#1 [J-006942-05], 5-GGGAAAAGCTTGACGATTA-3; oligonucleotide 
#2 [J-006942-06], 5-AGAGAGACTTTACTGTTTA-3; oligonucleotide #3 
[J-006942-07], 5-GGGAGCCGCTTACAAGAAA-3; and oligonucleotide 
#4 [J-006942-08], 5-TGACAGGCGTCTTGGCTTT-3; Thermo Fisher Scien-
tific). A custom US2-specific siRNA was transfected as a positive control se-
quence, 5-CGATCCGAAGGCCGATTATGG-3. Cells were cultured for 60 h 
and then assayed by FACSCalibur (BD). Data were analyzed with FlowJo 
(Tree Star, Inc.). Z scores were used to standardize our data, which had a 
normal distribution (99% of data had Z scores between 2 and 2), to 
allow comparisons both across siRNA plates and between US2 depletion 
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fluoride membranes, blocked with 5% dried milk (Marvel; Premier Interna-
tional Foods Ltd) in 0.2% PBS Tween (NBS Biologicals) for 30 min. Mem-
branes were probed with specific primary antibodies for 1 h at room 
temperature or overnight at 4°C, washed, and then incubated with 
1:10,000 dilutions of HRP-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories). Reactive bands were visualized by ECL 
(GE Healthcare) with SuperSignal West Pico or West Dura reagent (Thermo 
Fisher Scientific).
Online supplemental material
Fig. S1 shows that GFP-HLA-A2 is degraded in a proteasome-dependent 
fashion in the presence of US2. Fig. S2 shows that four independent TRC8 
siRNAs rescue US2-mediated MHC I degradation. Fig. S3 shows that TRC8 
associates with US2, MHC I, and SPP. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200906110/DC1.
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